Sugi Predict

Sugi Predict / Compounds / SCHEMBL18366270

SCHEMBL18366270

SCHEMBL18366270

NN1C(=O)CCC1c1ccccc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CHRM2 P08172 1/20 0.47
▸ CHRM4 P08173 1/20 0.47
▸ CHRM5 P08912 1/20 0.47
▸ CHRM1 P11229 1/20 0.47
▸ CHRM3 P20309 1/20 0.47
▸ SRD5A1 P18405 1/20 0.46
▸ L3MBTL1 Q9Y468 1/20 0.46
▸ KDM4E B2RXH2 2/20 0.45
▸ MEN1 O00255 2/20 0.45
▸ KMT2A Q03164 2/20 0.45
▸ CYP3A4 P08684 1/20 0.45
▸ THRB P10828 1/20 0.45
▸ TSHR P16473 1/20 0.45
▸ THPO P40225 1/20 0.45
▸ MAPK1 P28482 1/20 0.45
▸ NPSR1 Q6W5P4 1/20 0.45
▸ HDAC1 Q13547 1/20 0.40
▸ HDAC8 Q9BY41 1/20 0.40
▸ HDAC6 Q9UBN7 1/20 0.40
▸ DDB1 Q16531 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20646025 1.00 CHRM2 (0.47) CHRM2CHRM4CHRM5CHRM1CHRM3
SCHEMBL12918110 0.89 CHRNB2 (0.44) CHRM2CHRM4CHRM5CHRM1CHRM3
SCHEMBL11708369 0.81 KDM4E (0.66) CHRM2CHRM4CHRM5CHRM1CHRM3
SCHEMBL13225803 0.81 KDM4E (0.66) CHRM2CHRM4CHRM5CHRM1CHRM3
SCHEMBL11133372 0.80 RIPK1 (0.45) KMT2ATSHRCHRNB2CHRNB4CHRNA3
SCHEMBL11133370 0.80 RIPK1 (0.45) KMT2ATSHRCHRNB2CHRNB4CHRNA3
SCHEMBL3739324 0.79 HDAC6 (0.54) CHRM2CHRM4CHRM5CHRM1CHRM3
SCHEMBL28413243 0.77 L3MBTL1 (0.49) CHRM2CHRM4CHRM5CHRM1CHRM3
SCHEMBL20282540 0.77 CHRNB2 (0.39) CHRM2CHRM4CHRM5CHRM1CHRM3
SCHEMBL11477337 0.77 CHRM2 (0.57) CHRM2CHRM4CHRM5CHRM1CHRM3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12630554-B2 Pyrimidinone compounds and uses thereof HUTCHISON MEDIPHARMA LIMITED (CN) 2026-05-19 — — US disclosed
WO-2025217212-A1 MAC1 INHIBITORS AND USES THEREOF THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2025-10-16 — — WO disclosed
US-20240002388-A1 PYRIMIDINONE COMPOUNDS AND USES THEREOF HUTCHISON MEDIPHARMA LIMITED (CN) 2024-01-04 — — US disclosed
EP-3704097-B1 BICYCLIC SULFONES AND SULFOXIDES AND METHODS OF USE THEREOF HOFFMANN LA ROCHE (CH) 2023-10-25 — — EP disclosed
EP-4200281-A1 PYRIMIDINONE COMPOUNDS AND USES THEREOF Hutchison Medipharma Limited (CN) 2023-06-28 — — EP disclosed
CN-116249696-A Pyrimidinone compounds and use thereof 和记黄埔医药（上海）有限公司 2023-06-09 — — CN disclosed
US-20230002391-A1 BICYCLIC SULFONES AND SULFOXIDES AND METHODS OF USE THEREOF GENENTECH, INC. (US) 2023-01-05 — — US disclosed
EP-3978492-A1 BICYCLIC COMPOUND AS RIP-1 KINASE INHIBITOR AND APPLICATION THEREOF Medshine Discovery Inc. (CN) 2022-04-06 — — EP disclosed
WO-2022037585-A1 PYRIMIDINONE COMPOUNDS AND USES THEREOF HUTCHISON MEDIPHARMA LIMITED (CN) 2022-02-24 — — WO disclosed
WO-2022037585-A1 PYRIMIDINONE COMPOUNDS AND USES THEREOF HUTCHISON MEDIPHARMA LIMITED (CN) 2022-02-24 — — WO disclosed
WO-2020239074-A1 BICYCLIC COMPOUND AS RIP-1 KINASE INHIBITOR AND APPLICATION THEREOF 南京明德新药研发有限公司 2020-12-03 — — WO disclosed
US-20190127382-A1 BICYCLIC SULFONES AND SULFOXIDES AND METHODS OF USE THEREOF GENENTECH, INC. (US) 2019-05-02 — — US disclosed
US-20190100530-A1 BICYCLIC KETONE COMPOUNDS AND METHODS OF USE THEREOF GENENTECH, INC. (US) 2019-04-04 — — US disclosed
US-20180170927-A1 INHIBITORS OF RIP1 KINASE AND METHODS OF USE THEREOF GENENTECH, INC. (US) 2018-06-21 — — US disclosed
US-20180170927-A1 INHIBITORS OF RIP1 KINASE AND METHODS OF USE THEREOF GENENTECH, INC. (US) 2018-06-21 — — US disclosed
CN-107849023-A Bicyclic lactams and methods of use thereof 豪夫迈·罗氏有限公司 2018-03-27 — — CN disclosed
WO-2017004500-A9 BICYCLIC LACTAMS AND METHODS OF USE THEREOF GENENTECH, INC. (US) 2017-11-30 — — WO disclosed
US-20170008877-A1 BICYCLIC LACTAMS AND METHODS OF USE THEREOF GENENTECH, INC. (US) 2017-01-12 — — US disclosed
US-20170008877-A1 BICYCLIC LACTAMS AND METHODS OF USE THEREOF GENENTECH, INC. (US) 2017-01-12 — — US disclosed
WO-2017004500-A1 BICYCLIC LACTAMS AND METHODS OF USE THEREOF GENENTECH, INC. (US) 2017-01-05 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190127382-A1 BICYCLIC SULFONES AND SULFOXIDES AND METHODS OF USE THEREOF RB1, CCNE2, RPS3A CHRM2 1920/4885CHRM4 3269/4885CHRM5 2561/4885
US-20190100530-A1 BICYCLIC KETONE COMPOUNDS AND METHODS OF USE THEREOF HSD17B7, CYP11B1, CYP11B2 CHRM2 1333/4885CHRM4 1497/4885CHRM5 1801/4885
US-20240002388-A1 PYRIMIDINONE COMPOUNDS AND USES THEREOF TYMP, DPYD, DHFR CHRM2 4571/4885CHRM4 4623/4885CHRM5 3866/4885
US-20180170927-A1 INHIBITORS OF RIP1 KINASE AND METHODS OF USE THEREOF RIPK1, RIPK2, RIPK4 CHRM2 4857/4885CHRM4 4775/4885CHRM5 4842/4885
US-20170008877-A1 BICYCLIC LACTAMS AND METHODS OF USE THEREOF LSS, LPXN, CYP1B1 CHRM2 2025/4885CHRM4 2733/4885CHRM5 1914/4885
US-12630554-B2 Pyrimidinone compounds and uses thereof CYP2D6, TPMT, CYP2B6 CHRM2 393/4885CHRM4 460/4885CHRM5 216/4885
US-20230002391-A1 BICYCLIC SULFONES AND SULFOXIDES AND METHODS OF USE THEREOF RB1, CCNE2, RPS3A CHRM2 1920/4885CHRM4 3269/4885CHRM5 2561/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.